Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1323 of 5804
-
New hope for tough leukemia: first human trial of KK2845 begins
Disease control Recruiting nowThis is the first in human study of KK2845. This clinical trial consists of Part 1 (Dose Escalation) and Part 2 (Backfill). For patients with relapsed or refractory acute myeloid leukemia (AML) and other Hematologic Malignancies, in Part 1, the tolerability of KK2845 will be eva…
Phase: PHASE1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy aims to control bladder cancer without surgery
Disease control Recruiting nowTo learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill aims to protect kidneys in diabetes patients
Disease control Recruiting nowThe goal of this clinical trial is to to investigate whether the drug R3R01 has a beneficial effect on the amount of protein excreted in the urine in adult patients (above 18 years of age) with type 2 diabetes and resulting kidney disease. The main questions it aims to answer ar…
Phase: PHASE2 • Sponsor: River 3 Renal Corp. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill RAP-219 tested for stubborn seizures
Disease control CompletedThis is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
Phase: PHASE2 • Sponsor: Rapport Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New migraine pill shows promise in large trial
Symptom relief CompletedThis study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
Phase: PHASE2 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
New hope for rare blood disorder: ravulizumab trial shows promise in china
Disease control CompletedThe primary objective of this study is to evaluate the efficacy of ravulizumab in adult participants with PNH.
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Zapping the brain to fight forgetfulness: new dementia trial launches
Symptom relief Recruiting nowThis research investigates the effect of different frequencies of tACS (0 Hz, 30 Hz, 50 Hz, 70 Hz, 90 Hz) and tRNS with cognitive exercises in a regimen protocol of 4 weeks, everyday (Monday to Friday). The study design is a longitudinal study design in which participants receive…
Phase: NA • Sponsor: University of Manitoba • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Shocking the vagus nerve: new hope for stroke recovery?
Disease control Recruiting nowVagal Nerve Stimulation is a novel proven therapy for patients with chronic ischemic stroke. The primary objective of this registry is to assess the safety of vagal nerve stimulation for stroke recovery through monitoring the occurrence of serious adverse events associated with t…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Midwife-Led birth units may boost Parents' mental health years after childbirth
Knowledge-focused CompletedMajority of pregnancies and childbirths in France occur without complication. While the impact of care failure on maternal and neonatal morbi-mortality is now well- established, the literature reveals that an overmedicalization of pregnancy and childbirth care is not associated w…
Sponsor: Rennes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
One shot, two viruses: new vaccine targets RSV and hMPV in seniors
⭐️ VACCINE ⭐️ CompletedVAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine candidate and RSV vaccine.
Phase: PHASE1 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:59 UTC
-
New study hopes to spot cancer early in NF1 patients
Knowledge-focused Recruiting nowBackground: Neurofibromatosis type 1 (NF1) is a genetic disease that can cause many symptoms. About half of people with NF1 will develop benign (noncancerous) tumors along nerves in the skin, brain, and other parts of the body. Sometimes, though, these tumors can become cancerou…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
New drug trial aims to tame hardening skin and lung damage in scleroderma
Disease control Recruiting nowThe purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Blood test may spot head and neck Cancer's return
Knowledge-focused Recruiting nowThis is a single-center, non-interventional, observational study that evaluates the correlation of circulating tumor DNA (ctDNA) testing to cancer relapse for participants with squamous cell carcinomas (HNC) of the head and neck mucosa and skin after curative-intent primary radia…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New PET tracer could sharpen colon cancer staging
Diagnosis Recruiting nowWhole body CT is the primary imaging method in staging and follow-up of colon cancer. Conventional PET-CT with 18F-labeled fluorodeoxyglucose (18F-FDG) has its limitations and has a secondary role in colon cancer protocols. A new PET tracer, fibroblast activation protein inhibito…
Phase: PHASE2, PHASE3 • Sponsor: Turku University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
Immune cells trained to fight ovarian cancer in new trial
Disease control Recruiting nowThe goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: CIML NK (cellu…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for diabetes-related vision loss: experimental drug faces final test
Disease control Recruiting nowA multicenter, randomized, double-blind, parallel-group, active-controlled non-inferiority trial. A total of 406 subjects with diabetic macular edema (DME) were planned for enrollment. After screening, eligible subjects were randomized in a 1:1 ratio to the treatment group or the…
Phase: PHASE3 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo aims to stall lung Cancer's spread
Disease control Recruiting nowThis phase II trial tests how well biologically guided radiation therapy (BgRT) and stereotactic body radiation therapy (SBRT) with osimertinib works for the treatment of EGFR positive non-small cell lung carcinoma that has spread from where it first started (primary site) to a l…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Single dose of esketamine during surgery may ward off Post-Op depression in ovarian cancer patients
Prevention CompletedThe goal of this clinical trial is to learn if intraoperative administration of esketamine would prevent or mitigate postoperative depressive symptoms after cytoreductive surgery in ovarian cancer. The main questions it aims to answer are: * Whether a single low dose of esketami…
Phase: NA • Sponsor: Zhejiang Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 09:08 UTC
-
Experimental virus therapy takes on deadly brain cancer
Disease control Recruiting nowThis is a Phase 1/2a, open-label study to evaluate the safety, tolerability, immunogenicity, and preliminary clinical activity of RZ-001 administered in combination with VGCV in subjects with hTERT-positive GBM.
Phase: PHASE1, PHASE2 • Sponsor: Rznomics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:50 UTC
-
New hope for advanced cancers: experimental drug ACR-2316 enters first human trial
Disease control Recruiting nowThis is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
Phase: PHASE1 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC